Endomedica
Endomedica GmbH, established in 2014 in Halle/Saale, specializes in the research and development of innovative transdermal therapeutic systems for the treatment of endocrine, oncological, and internal diseases. The company is a registered pharmaceutical entrepreneur since 2018, acting as an approval holder and wholesaler of medicines, with a focus on developing safe, rapid, and minimally painful drug delivery systems. Endomedica is engaged in various research projects, collaborations, and has a pipeline of innovative products including OLED-based patches for photodynamic therapy.
Industries
Nr. of Employees
small (1-50)
Products
Leuprorelin solid implant with applicator
An implantable solid formulation of leuprorelin supplied with a single-use applicator designed to enable rapid and pain-reduced subcutaneous implantation for hormone-dependent prostate cancer treatment.
Leuprorelin solid implant with applicator
An implantable solid formulation of leuprorelin supplied with a single-use applicator designed to enable rapid and pain-reduced subcutaneous implantation for hormone-dependent prostate cancer treatment.
Services
Collaborative research and development services to design and develop transdermal patches, active TTS and implantable formulations in partnership with research institutes and industry partners.
Development and delivery of functional prototypes (e.g., OLED-containing patches) as project milestones in funded programs.
In-country production of medicinal products and device components for company products.
Operations as a registered pharmaceutical entrepreneur including acting as marketing authorization holder and performing wholesale distribution of medicines under national regulatory oversight.
Collaborative research and development services to design and develop transdermal patches, active TTS and implantable formulations in partnership with research institutes and industry partners.
Development and delivery of functional prototypes (e.g., OLED-containing patches) as project milestones in funded programs.
In-country production of medicinal products and device components for company products.
Operations as a registered pharmaceutical entrepreneur including acting as marketing authorization holder and performing wholesale distribution of medicines under national regulatory oversight.
Expertise Areas
- Transdermal drug delivery
- Implantable drug delivery systems
- Photodynamic therapy device development
- Printed electronics for medical devices
Key Technologies
- Transdermal therapeutic systems (TTS)
- Implantable solid drug implants
- Monochromatic OLEDs for photodynamic therapy
- Printed-electronics power sources
News & Updates
Endomedica successfully completed the SmartEEs2 Horizon 2020 project with the delivery of a functional prototype, developing monochromatic OLED technology for photodynamic therapy, with partners Fraunhofer FEP and Upperion SAS.
Endomedica was a guest speaker at the hybrid 'pro flex' congress in Dresden, presenting on the development of an innovative OLED patch for photodynamic therapy.
Endomedica received the final approval for participation in the ZIM joint project 'BAKE', developing an OLED-based patch for pain-reduced, year-round home photodynamic therapy for actinic keratosis, with a funding volume of €180,000.
Endomedica successfully completed the SmartEEs2 Horizon 2020 project with the delivery of a functional prototype, developing monochromatic OLED technology for photodynamic therapy, with partners Fraunhofer FEP and Upperion SAS.
Endomedica was a guest speaker at the hybrid 'pro flex' congress in Dresden, presenting on the development of an innovative OLED patch for photodynamic therapy.
Endomedica received the final approval for participation in the ZIM joint project 'BAKE', developing an OLED-based patch for pain-reduced, year-round home photodynamic therapy for actinic keratosis, with a funding volume of €180,000.